archTIS Ltd (ASX:AR9, OTCQB:ARHLF) has secured a services contract worth $250,000 with Copper River Technologies to develop new functionality for its NC Protect software on behalf of the US Department of Defense (DoD).
Under the engagement — procured and managed by Copper River, a US-based federal contract holder and reseller of archTIS products — the company will build features requested by the DoD to enable deeper integration with existing Defense classification systems and Microsoft tools, including within the Microsoft DoD365 environment. The work will be carried out in a highly classified setting.
Orthocell Ltd (ASX:OCC, OTC:ORHHF) has received firm commitments to raise A$30 million (before costs) via an institutional placement that attracted strong demand from both international and domestic investors, including several new US institutions alongside other institutional and high-net-worth participants. The placement comprises 23,076,923 new fully paid ordinary shares at $1.30 per share. The offer price represents a 9.1% discount to the last traded price of $1.43.
The money raised will strengthen OCC’s balance sheet to “well over” A$50 million in cash with no debt, leaving the company fully funded to execute its global commercialisation strategy with a near-term focus on the United States rollout of its flagship nerve repair device, Remplir.
Sonoro Gold Corp (TSX-V:SGO, OTCQB:SMOFF) announced that it is increasing the size of its previously announced non-brokered private placement to 20 million units, representing gross proceeds of C$4 million.
The company said the offering price will remain at $0.20 per unit.
HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) shares were up on Thursday, after it announced breakthrough results confirming both mantle helium and geological hydrogen potential at its flagship Rudyard Project in Montana.
The small-cap explorer, in a statement, said the findings indicate "significant potential for geological hydrogen generation" at the project.
Iofina PLC (AIM:IOF, OTC:IOFNF) shares made gains on Thursday after telling investors it has achieved record quarterly production of 215.8 metric tonnes of crystalline iodine in Q3 2025, a 32% increase from the same period last year.
Output was driven by its eighth operational IOsorb plant, IO#11, which began production in July and lifted September volumes to 75 MT.
Standard Uranium Ltd (TSX-V:STND, OTCQB:STTDF) has announced preliminary results from its 2025 exploration program at the Rocas uranium project in northern Saskatchewan, where fieldwork confirmed strong surface radioactivity and identified new uranium and rare earth element (REE) showings.
The Rocas project, which spans 4,002 hectares about 75 kilometers southwest of the Key Lake Mine, is currently under a three-year earn-in option agreement with Collective Metals.
Power Metallic Mines Inc (TSX-V:PNPN, OTCQB:PNPNF) provided an update on preliminary metallurgical studies on the Lion deposit at its Nisk Project in Quebec, saying work to date has shown that the copper mineralization is contained within coarse grained chalcopyrite and cubanite, both which should respond well to conventional sulphide concentration methods.
Power Metallic Mines noted that overall, the character of the mineralization suggests good recoveries of copper sulphides, and these initial metallurgical tests will determine the recovery potential of the platinum group elements (PGEs), gold, silver, and nickel, which are expected to report within a conventional sulphide concentrate.
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has appointed Dr Bali Pulendran, a leading authority in systems immunology and vaccinology, to its Research Advisory Board.
Dr Pulendran is the Violetta L. Horton Professor at Stanford University School of Medicine, Director of the Institute for Immunity, Transplantation and Infection, and a Fellow at ChEM-H (Chemistry, Engineering and Medicine for Human Health).
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has given investors something to cheer about. The AIM-listed biotech climbed 3.3% to 8.25p after reporting encouraging progress in its early-stage trial for a peanut allergy vaccine.
The company said its phase I/IIa study, called PROTECT, has now safely completed dosing in healthy volunteers at the highest planned levels, with no signs of serious side effects or tolerability issues.
Shares in IXICO PLC (LSE:IXI, OTC:PHYOF) climbed 4% to 13p after the neuroscience data firm reported a 13% rise in annual revenue to £6.5 million, exceeding market expectations.
The growth was driven by a mix of new contract wins, extensions to existing deals, and expansion into new areas within the neurodegenerative disease research market.
Anglo Asian Mining Plc (LSE:AAZ, OTC:AGXKF) told investors it has seen record quarterly copper production of 2,287 tonnes for the three months to 30 September 2025, a 250% increase on the prior quarter following first output from the Demirli mine and a full quarter from its operations at Gilar.
Gold production, meanwhile, rose to 6,798 ounces and silver to 41,605 ounces.
Allergy Therapeutics PLC (AIM:AGY, OTC:AGYTF) has reported further encouraging results from its ongoing phase I/IIa PROTECT trial, which is testing the safety and tolerability of its short-course peanut allergy vaccine, VLP Peanut.
The company says the candidate was well tolerated in both healthy volunteers and peanut-allergic patients, with no serious safety concerns observed across any dose level.
IXICO PLC (LSE:IXI, OTC:PHYOF) has delivered double-digit revenue growth for the year ended 30 September, with sales rising 13% to £6.5 million, up from £5.8 million a year earlier.
The neuroscience data specialist said growth was driven by new contract wins, extensions to existing partnerships, and an expansion into adjacent market areas.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the UK-based cancer diagnostics firm soon to be renamed CelLBxHealth, has appointed Peter Collins as interim chief executive and brought on Klaas de Boer as a senior board advisor.
The moves come as the company prepares for a strategic restructure and funding round in the final quarter of the year.
Coinsilium Group Limited (AQSE:COIN, OTCQB:CINGF) has restructured its board and signalled a strategic shift as it prepares for a busier phase of activity in the digital-asset sector, backed by a stronger balance sheet and a growing Bitcoin treasury.
The London-listed firm, which invests in blockchain and digital-asset ventures, raised around £17 million between May and August.
Provaris Energy Ltd (ASX:PV1, OTC:GBBLF) has established a new Innovation Centre in Fiskå, Norway, to advance fabrication and testing of its proprietary hydrogen (H₂) and liquid carbon dioxide (LCO₂) storage tanks using robotic laser-welding technology.
The facility, which has now completed commissioning of its robotic laser welding and handling systems, will recommence fabrication of the company’s hydrogen prototype tank this month — a key step towards final Class approvals for Provaris’ H₂Neo™ carrier design.
Lithium Universe Ltd (ASX:LU7, OTC:LUVSF) and research partner Macquarie University have reported a significant improvement in solar panel recycling process efficiency, confirming an 83% reduction in acid consumption using their Jet Electrochemical Silver Extraction (JESE) process.
The development marks another scientific validation of Lithium Universe’s growing photovoltaic (PV) recycling technology portfolio — a cornerstone of its dual strategy to close North America’s “lithium conversion gap” and pioneer sustainable recovery of valuable metals from solar waste.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has received regulatory clearance from the Danish Medicines Agency to begin its global pivotal trial of the DurAVR® transcatheter heart valve (THV) in patients with severe calcific aortic stenosis.
The company said patient enrolment at Danish centres is expected to start in the fourth quarter of 2025. Denmark is the first country to authorise participation in the study, dubbed PARADIGM — a prospective, randomised controlled trial comparing DurAVR against commercially available transcatheter aortic valve replacement (TAVR) devices.
Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has signed an agreement with WellStreet Urgent Care to advance testing and reimbursement pathways for its FebriDx® rapid host-response test through WellStreet’s joint venture with Piedmont Urgent Care in Atlanta, Georgia.
“We are excited to partner with WellStreet to bring FebriDx® into a high-throughput, clinically integrated setting,” Lumos Diagnostics CEO Doug Ward said. “This agreement will greatly assist in laying the groundwork for a scalable national roll-out, pending CLIA waiver. We also greatly value the role of PHASE Scientific and Pro-spectus in aiding in the rollout of this program.”
FireFly Metals Ltd (ASX:FFM, TSX:FFM, OTC:MNXMF) has unveiled another batch of outstanding drill results from its Green Bay Copper-Gold Project in Newfoundland, Canada, with new assays extending high-grade mineralisation by more than 650 metres beyond the current mineral resource boundary.
The headline result — 49 metres at 6.1% copper equivalent (CuEq) including 14.3 metres at 13.7% CuEq — marks one of the best intersections ever drilled at the Ming deposit and reinforces the company’s view that grades and thicknesses are improving with depth.